Titan Pharmaceuticals 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act 1934
Date of Report (Date of earliest event reported): December 30, 2011
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
Registrants telephone number, including area code:650-244-4990
(Former Name or Former Address, is Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
The information set forth under Item 5.02 of this Current Report on Form 8-K relating to the entry into amendments to the employment agreements of Marc Rubin and Sunil Bhonsle is hereby incorporated in this Item 1.01 by reference.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 30, 2011, Titan Pharmaceuticals, Inc., a Delaware corporation (the Company), entered into one-year extensions (the Extension Amendments) to the Employment Agreements dated May 16, 2009, as amended, by and between the Company and each of Marc Rubin, the Companys Executive Chairman, and Sunil Bhonsle, the Companys President (the Employment Agreements). Pursuant to the Extension Amendments, on January 3, 2012, Dr. Rubin and Mr. Bhonsle were granted options to purchase 250,000 and 300,00 shares of the Companys common stock, respectively, at an exercise price equal to the fair market value of the common stock on the date of grant, in accordance with the provisions of the Companys 2002 Incentive Plan. All of the other terms and conditions of the Employment Agreements remain the same.
Copies of the Extension Amendments with Dr. Rubin and Mr. Bhonsle are attached hereto as Exhibits 10.1 and 10.2, respectively, and the description thereof contained in this Current Report on the Form 8-K is qualified in its entirety by reference to such exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 4, 2012